



THANATOS

KICK-OFF MEETING 17TH-18TH SEPTEMBER 2026

123 SEBASTOPOL HOTEL
123 Bd de Sébastopol, Paris - France

AGENDA

Thursday 17th September

10:00 - 11:00 *Welcome Coffee & Registration*

Welcoming and Introduction

11:00 – 11:10 **Welcome by the Project Coordinator** – J.N. Tournier, CEA

11:10 – 11:25 **HERA Medical Countermeasures** – C. Wimmer, EU Directorate-General for Health Emergency Preparedness and Response Authority

11:25 – 11:55 **Overview and Vision of THANATOS** – A. Avril, IRBA

11:55 – 12:55 **Presentation of Partners and their Expertise in Relation to the THANATOS Project**
(ca. 5 minutes each)

1 **CEA** COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES FR - J.N. Tournier

2 **TUBS** TECHNISCHE UNIVERSITAET BRAUNSCHWEIG DE - M. Hust

3 **IRBA** MINISTERE DES ARMEES FR – A. Avril

4 **MABS** MABSILICO FR - V. Puard

5 **HZI** HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GM DE - M. Schubert

6 **INN-ACTA** INNOVATION ACTA SRL IT - L. Maccari

7 **NORTHX** NORTHX BIOLOGICS MATFORS AB SE - L. Lundin

8 **EURF** EUROFINS OPTIMED FR - L. Krebs-Drouot

9 **CPC** CENTRE PASTEUR CAMEROON CM - R. Njouom

10 **BSL** BIOSERVICE Scientific Laboratories Munich GmbH DE - R. Torka

13:00 – 14:00 *Light Lunch*

WP session I (20 min each + 10 min Q&A)

14:00 – 14:30 **WP1-3 Project Management** – J.N. Tournier, CEA; L. Maccari, INN-ACTA

14:30 – 15:00 **WP4 Antibody optimization** – R. Guerois, CEA; M. Hust, TUBS; H. Nozach, L. Bellanger, C. Almunia, CEA; T. Bourquard, MABS

15:00 – 15:30 **WP5 In vitro neutralization assays** – A. Ferrier, IRBA; D. D. Djuicy, CPC

15:30 – 16:00 **WP6 Prediction of stability and industrialization** – T. Bourquard, MABS

16:00 – 16:30 *Coffee Break & Group photo*



THANATOS

KICK-OFF MEETING 17TH-18TH SEPTEMBER 2026

123 SEBASTOPOL HOTEL
123 Bd de Sébastopol, Paris - France

AGENDA

- 16:30 – 17:00 **WP7-8 In vivo protection assay** – C. Herate, CEA IDMIT
- 17:00 – 17:30 **WP9-10 Antigen and Antibody production** – L. Lundin, NORTHX
- 17:30 – 18:00 **WP11 Antigen and Antibody production** – M. Hust, TUBS; M. Schubert, HZI
- 18:00 – 18:30 **WP12 Antigen and Antibody production** – L. Lundin, NORTHX
- 19:30 – 21:30 *Dinner Talks: Key Takeaways from Day One*

Friday 18th September

WP session II (20 min each + 10 min Q&A)

- 09:00 – 09:30 **WP13 Preclinical development** – R. Torka, BSL
- 09:30 – 10:00 **WP14-15 Clinical development phase** – L. Krebs-Drouot, EURF
- 10:00 – 10:30 *Coffee break*
- 10:30 – 11:00 **WP16-18 Communication, Dissemination and Exploitation** – L. Maccari, V. Franci, INN-ACTA
- 11:00 – 11:30 *Wrap up & Farewells*



Funded by
the European Union

Funded by the European Union under Grant Agreement No. 101288101. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Executive Agency (REA). Neither the European Union nor the granting authority can be held responsible for them.

Organization and Graphic project by:

Innovation Acta